Diagonal Bio AB (publ)
Stockholm Stock ExchangeTotal Valuation
Diagonal Bio AB (publ) carries a market capitalization of 20.20M, placing it among publicly traded companies globally.
| Market Cap | 20.20M |
| Enterprise Value | N/A |
Share Statistics
Diagonal Bio AB (publ) currently has 1.63B shares outstanding.
| Shares Outstanding | 1.63B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Diagonal Bio AB (publ) maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.05 |
| Quick Ratio | 0.81 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -731.08 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -32.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | -0.45 |
Stock Price Statistics
Diagonal Bio AB (publ)'s stock has declined approximately -83.94241% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -83.94241% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Diagonal Bio AB (publ) generated 293,000.00 in revenue and converted that into -9.44M in net income, yielding earnings per share of -0.01. EBITDA reached -9.50M, while operating income came in at -9.50M.
| Revenue | 293,000.00 |
| Gross Profit | 958,000.00 |
| Operating Income | -9.50M |
| Pretax Income | -9.44M |
| Net Income | -9.44M |
| EBITDA | -9.50M |
| EBIT | -9.50M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Total book value stands at -46.93M, with working capital of 2.24M providing operational flexibility.
| Cash & Cash Equivalents | 1.74M |
| Total Debt | N/A |
| Net Debt | -1.74M |
| Equity (Book Value) | -46.93M |
| Book Value Per Share | -0.05 |
| Working Capital | 2.24M |
Cash Flow
Diagonal Bio AB (publ) produced -8.45M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.45M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.45M |
| FCF Per Share | -0.01 |
Margins
Diagonal Bio AB (publ) operates with a gross margin of 326.96, reflecting its pricing power and cost economics. The operating margin of -3,243.69 and net profit margin of -3,222.87 provide insight into operational efficiency.
| Gross Margin | 326.96 |
| Operating Margin | -3,243.69 |
| Pretax Margin | -3,222.87 |
| Profit Margin | -3,222.87 |
| EBITDA Margin | -3,243.69 |
Stock Splits
Diagonal Bio AB (publ)'s most recent stock split took place on November 25, 2022 with a 103:175 split ratio.
| Last Split Date | 11/25/2022 |
| Split Ratio | 103:175 |
Scores
Diagonal Bio AB (publ) posts an Altman Z-Score of -23.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -23.30 |